A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

To be considered for this study, you need to have a diagnosis of multiple sclerosis (MS) and have experienced muscle stiffness (spasticity) related to MS for at least six months. Your muscle stiffness needs to be at a certain level in specific muscle groups, including at least one leg muscle group (but not just your ankle muscles).

There are also some reasons why you might not be able to join. For example, if you have other conditions that cause spasticity or if you've recently had an MS flare-up that required treatment. You also shouldn't have a history of substance abuse or be taking certain medications for spasticity that you can't stop before the study. Specifically, you shouldn't have used any cannabis-related products, including CBD or THC, within 30 days before the study starts. Participants must be between 18 and 70 years old.

This study involves taking either the new medicine, BMS-986368, or a placebo, which looks identical but has no active ingredients. You would have several visits to the study clinic where various assessments will be done to check how you are doing, including how your spasticity is responding and any side effects you might experience. This will involve physical examinations and other tests. You will be closely monitored by medical staff throughout the study. The total duration of your participation in the study, including all visits and follow-up, will be explained in detail by the study team.